In a filing, Palisade Bio Inc revealed its CEO, CFO, Director Finley John David acquired Company’s shares for reported $4692.0 on Feb 06 ’24. In the deal valued at $0.47 per share,10,000 shares were bought. As a result of this transaction, Finley John David now holds 84,649 shares worth roughly $0.5 million.
Then, Williams Donald Allen bought 10,000 shares, generating $6,050 in total proceeds. Upon buying the shares at $0.60, the Director now owns 30,000 shares.
Before that, Finley John David bought 10,000 shares. Palisade Bio Inc shares valued at $5,590 were divested by the CEO, CFO, Director at a price of $0.56 per share. As a result of the transaction, Finley John David now holds 74,649 shares, worth roughly $0.44 million.
Price Performance Review of PALI
On Tuesday, Palisade Bio Inc [NASDAQ:PALI] saw its stock jump 20.08% to $5.92. Over the last five days, the stock has lost -0.17%. Palisade Bio Inc shares have fallen nearly -33.11% since the year began. Nevertheless, the stocks have fallen -77.58% over the past one year. While a 52-week high of $36.60 was reached on 01/29/24, a 52-week low of $3.82 was recorded on 04/12/24. SMA at 50 days reached $5.76, while 200 days put it at $10.58. A total of 23.35 million shares were traded, compared to the trading of 29800.0 shares in the previous session.
Levels Of Support And Resistance For PALI Stock
The 24-hour chart illustrates a support level at 5.00, which if violated will result in even more drops to 4.09. On the upside, there is a resistance level at 7.50. A further resistance level may holdings at 9.09. The Relative Strength Index (RSI) on the 14-day chart is 53.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 63.98%. Stochastics %K at 23.44% indicates the stock is a holding.
